Endostatin in Treating Patients With Advanced Solid Tumors

DISEASE CHARACTERISTICS: * Histologically proven advanced solid tumor for which no standard curative therapy exists * Must be amenable to biopsy At least 1 site of measurable disease outside of irradiated field * No brain metastases by CT or MRI scan PATIENT CHARACTERISTICS: * Age: 18 and over * Performance status: ECOG 0-1 * WBC greater than 3,000/mm3 * Absolute neutrophil count greater than 1,500/mm3 * Platelet count greater than 100,000/mm3 * Hemoglobin greater than 10 g/dL * Bilirubin less than 1.5 times upper limit of normal (ULN) * ALT and AST less than 2.0 times ULN * PT/PTT less than 1.5 times ULN * Creatinine less than 1.5 mg/dL OR creatinine clearance greater than 60 mL/min * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No concurrent uncontrolled medical or psychiatric disorder * No history of bleeding diathesis PRIOR CONCURRENT THERAPY: * No concurrent over the counter biologic agents (e.g., shark cartilage) * At least 3 weeks since prior chemotherapy (6 weeks since nitrosoureas or mitomycin) * No more than 3 prior chemotherapy regimens for metastatic or recurrent disease (ECOG 1) * Prior adjuvant chemotherapy for nonmetastatic disease allowed * Concurrent stable dose of hormone replacement therapy allowed * At least 3 weeks since prior radiotherapy * No concurrent radiotherapy * At least 24 hours since minor surgery (e.g., central venous placement) * At least 4 weeks since major surgery (e.g., laparotomy, thoracotomy, or craniotomy) * At least 30 days since other prior investigational agents * No concurrent herbal remedies * No concurrent usage of products containing heparin * No other concurrent anticancer therapy * Concurrent multivitamins allowed